IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies

HOUSTON--(BUSINESS WIRE)--IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. Redefining the Therapeutic Paradigm: Generating New Human Muscle Duchenne muscular dystrophy (DMD) leads to progressive skeletal muscle loss, severe cardiac fibrosis, and premature death fr